James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 ‘Drunken Psycho’ Stocks to Buy

The market may actually be a drunken psycho from time to time, but that’s not necessarily a bad thing. That instability often creates a nice batch of stocks to buy … like these.

Why RPM International, Helmerich & Payne and Radian Group Are 3 of Today’s Worst Stocks

Radian Group, RPM International and Helmerich & Payne were Wednesday's worst of the worst. Here's what investors need to know about their setbacks.

ARNA Stock Pops, And There’s Plenty More Where That Came From

ARNA bolted higher on Wednesday because -- as it turns out -- Arena Pharmaceuticals has a pipeline, and isn't a one-trick (Belviq) pony.

Why Herbalife, Michael Kors Holdings and Integrated Device Technology Are 3 of Today’s Worst Stocks

Integrated Device Technology, Herbalife and Michael Kors Holdings were the weakest of the weak on Tuesday. Here's what up-ended each one of these stocks.

This Particular Stock Bubble Is Bound to Burst in 2015

Healthcare stocks may have been all the rage in 2014, but time, hubris and exuberance have finally caught up with the sector.